Loading...

Meyeon Park, MD, MAS

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Phone415-476-2173
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of PennsylvaniaM.D.2006School of Medicine
    Yale-New Haven Hospital2009Internal Medicine Residency
    University of California, San FranciscoM.A.S. in Clinical Research2012 Graduate Division (Advanced Training in Clinical Research)
    University of California, San Francisco2013Nephrology fellowship
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    National PKD Foundation2017Physician Gratitude Award
    Doris Duke Charitable Foundation2015  - 2018Clinical Scientist Development Award
    NIH NIDDK2013  - 2018K23 Career Development Award
    UCSF CTSI2015  - 2016Pilot for Junior Investigators in Basic and Clinical/Translational Sciences
    UCSF Department of Medicine2014  - 2015Centers of Excellence in Patient Research Pilot Award

    Collapse Overview 
    Collapse Overview
    My research focuses on the early diagnosis of kidney hypoxia, injury, and disease and the influence of cardiovascular disease on kidney disease onset and progression. Clinically, I see patients with all manifestations of hypertension and kidney disease, with a special focus on patients with polycystic kidney disease. I am the medical director of the UCSF PKD Center of Excellence and principal investigator of the UCSF Cardiovascular Risk After Kidney Transplantation (CARAKTER) study.

    EDUCATION
    College: Harvard College
    Medical School: University of Pennsylvania School of Medicine
    Other Graduate Training: University of California, San Francisco, MAS
    Internal Medicine Residency: Yale-New Haven Hospital
    Nephrology Fellowship: University of California, San Francisco

    Collapse Research 
    Collapse Research Activities and Funding
    Living Donor Extended Time Outcomes (LETO) Study
    NIH/NIDDK R01DK120551Jun 1, 2019 - May 31, 2024
    Role: Co-Principal Investigator
    (1/1) Maximizing geographic and scientific reach through a Northern California APOLLO Network: application for Clinical Center
    NIH/NIDDK U01DK116043Sep 25, 2017 - May 31, 2022
    Role: Co-Principal Investigator
    Why do patients with cardiovascular disease develop kidney injury and disease?
    NIH/NIDDK K23DK099238Sep 1, 2013 - Jun 30, 2018
    Role: Principal Investigator
    Subclinical and clinical heart disease and the effect on kidney injury and diseas
    NIH/NIDDK F32DK093231Jan 1, 2012 - Dec 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lassen MCH, Qasim AN, Biering-Sørensen T, Reeh JLT, Watnick T, Seliger SL, Chen H, Sawan MA, Nguyen D, Li Y, Hong SN, Park M. Cardiac function assessed by myocardial deformation in adult polycystic kidney disease patients. BMC Nephrol. 2019 Aug 16; 20(1):324. PMID: 31419965.
      View in: PubMed
    2. Norton JM, Ali K, Jurkovitz CT, Kiryluk K, Park M, Kawamoto K, Shang N, Navaneethan SD, Narva AS, Drawz P. Development and Validation of a Pragmatic Electronic Phenotype for CKD. Clin J Am Soc Nephrol. 2019 Aug 12. PMID: 31405830.
      View in: PubMed
    3. Lentine KL, Holscher CM, Naik AS, Lam NN, Segev DL, Garg AX, Axelrod D, Xiao H, Henderson ML, Massie AB, Kasiske BL, Hess GP, Hsu CY, Park M, Schnitzler MA. Postdonation eGFR and New-Onset Antihypertensive Medication Use After Living Kidney Donation. Transplant Direct. 2019 Aug; 5(8):e474. PMID: 31576370.
      View in: PubMed
    4. Wulczyn K, Perez-Reyes E, Nussbaum RL, Park M. Primary aldosteronism associated with a germline variant in CACNA1H. BMJ Case Rep. 2019 May 23; 12(5). PMID: 31126930.
      View in: PubMed
    5. Freise J, Tavakol M, Gao Y, Klein O, Lee BK, Freise C, Park M. The Effect of Enlarged Kidneys on Calculated Body Mass Index Categorization in Transplant Recipients With ADPKD. Kidney Int Rep. 2019 Apr; 4(4):606-609. PMID: 30993236.
      View in: PubMed
    6. Chirumamilla R, Mina D, Siyahian S, Park M. Subclinical metabolic and cardiovascular abnormalities in autosomal dominant polycystic kidney disease?. Clin Nephrol. 2018 Oct; 90(4):237-245. PMID: 30106364.
      View in: PubMed
    7. Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. Am J Kidney Dis. 2019 Jan; 73(1):51-61. PMID: 30037726.
      View in: PubMed
    8. Cullaro G, Park M, Lai JC. "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology. 2018 11; 68(5):1953-1960. PMID: 29698588.
      View in: PubMed
    9. Park M, Nussbaum RL. Recurrent Renal Cysts in a Transplanted Kidney. Ann Intern Med. 2018 11 06; 169(9):657-658. PMID: 29971405.
      View in: PubMed
    10. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. Associations of TNFR1 with kidney function outcomes by age, gender, and baseline kidney function status: Data from the Heart and Soul Study. Data Brief. 2017 Oct; 14:366-370. PMID: 28831402.
      View in: PubMed
    11. Tran WC, Huynh D, Chan T, Chesla CA, Park M. Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease. BMC Nephrol. 2017 Jul 05; 18(1):214. PMID: 28679364.
      View in: PubMed
    12. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: Data from the Heart and Soul Study. Atherosclerosis. 2017 Aug; 263:68-73. PMID: 28601698.
      View in: PubMed
    13. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, Bonventre JV, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol. 2017 May 08; 12(5):761-771. PMID: 28254771.
      View in: PubMed
    14. Park M, Shlipak MG, Thiessen-Philbrook H, Garg AX, Koyner JL, Coca SG, Parikh CR. Association of Peak Changes in Plasma Cystatin C and Creatinine With Death After Cardiac Operations. Ann Thorac Surg. 2016 Apr; 101(4):1395-401. PMID: 26921980.
      View in: PubMed
    15. Park M, Shlipak MG, Vittinghoff E, Katz R, Siscovick D, Sarnak M, Lima JA, Hsu CY, Peralta CA. Associations of kidney injury markers with subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Clin Nephrol. 2015 Dec; 84(6):358-63. PMID: 26558369.
      View in: PubMed
    16. Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, Cai J, Hunsicker LG, Park M, Bennett M, Liu KD, Hsu CY. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016 Jul; 27(7):2109-21. PMID: 26538631.
      View in: PubMed
    17. Park M, Kulkarni A, Beatty A, Ganz P, Regan M, Vittinghoff E, Whooley M. Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study. Atherosclerosis. 2015 Dec; 243(2):546-52. PMID: 26523992.
      View in: PubMed
    18. Wu EH, Wojciechowski D, Chandran S, Yeh BM, Park M, Westphalen A, Wang ZJ. Prevalence of abdominal aortic calcifications in older living renal donors and its effect on graft function and histology. Transpl Int. 2015 Oct; 28(10):1172-8. PMID: 26011061.
      View in: PubMed
    19. Park M. Islands in the stream: the risk of kidney disease from cardiovascular disease. Am J Kidney Dis. 2015 May; 65(5):647-9. PMID: 25919498.
      View in: PubMed
    20. Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, Park M, Sarnak M, Seliger S, Shlipak M. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015 Feb 06; 10(2):205-14. PMID: 25605700.
      View in: PubMed
    21. Chong KC, Owens CD, Park M, Alley HF, Boscardin WJ, Conte MS, Gasper WJ, Grenon SM. Relationship between kidney disease and endothelial function in peripheral artery disease. J Vasc Surg. 2014 Dec; 60(6):1605-11. PMID: 25441679.
      View in: PubMed
    22. Park M, Vittinghoff E, Shlipak MG, Mishra R, Whooley M, Bansal N. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study. Am Heart J. 2014 Dec; 168(6):931-9.e2. PMID: 25458658.
      View in: PubMed
    23. Park M, Hsu CY. An ACE in the hole for patients with advanced chronic kidney disease? JAMA Intern Med. 2014 Mar; 174(3):355-6. PMID: 24342932.
      View in: PubMed
    24. Parikh CR, Butrymowicz I, Yu A, Chinchilli VM, Park M, Hsu CY, Reeves WB, Devarajan P, Kimmel PL, Siew ED, Liu KD. Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis. 2014 Apr; 63(4):567-72. PMID: 24200462.
      View in: PubMed
    25. Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak MG. Role of soluble endothelial cell-selective adhesion molecule biomarker in albuminuria and kidney function changes in patients with coronary artery disease: the Heart and Soul Study. Arterioscler Thromb Vasc Biol. 2014 Jan; 34(1):231-6. PMID: 24177327.
      View in: PubMed
    26. Park M, Vittinghoff E, Liu KD, Shlipak MG, Hsu CY. Urine Biomarkers Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) Have Different Patterns in Heart Failure Exacerbation. Biomark Insights. 2013; 8:15-8. PMID: 23531625.
      View in: PubMed
    27. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012 Oct; 23(10):1725-34. PMID: 22935481.
      View in: PubMed
    28. Park M, Shlipak MG, Katz R, Agarwal S, Ix JH, Hsu CY, Peralta CA. Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2012 Jul; 7(7):1137-44. PMID: 22580783.
      View in: PubMed
    29. Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR. Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am J Nephrol. 2010; 31(5):408-18. PMID: 20375494.
      View in: PubMed
    30. Park M, Hryniewicz K, Setaro JF. Pheochromocytoma presenting with myocardial infarction, cardiomyopathy, renal failure, pulmonary hemorrhage, and cyclic hypotension: case report and review of unusual presentations of pheochromocytoma. J Clin Hypertens (Greenwich). 2009 Feb; 11(2):74-80. PMID: 19222671.
      View in: PubMed
    31. Park M, Davidson R, Fox K. Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer. Semin Oncol. 2006 Dec; 33(6):664-71. PMID: 17145346.
      View in: PubMed